EUVIMEDEUVIMED entdecken
Kohortenstudie

Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study

Taisa Kohut, Andrea Tou, Emily Carr, Stavra Xanthakos, Ana Catalina Arce-Clachar, Rima Fawaz, Pamela L Valentino, Jennifer Panganiban, Marialena Mouzaki

Journal of Parenteral and Enteral Nutrition · 2025-04 · 49 (3) · 308-313

DOI: 10.1002/jpen.2722 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Parenteral and Enteral Nutrition, online erschienen am 25.12.2024. Verfasst von Taisa Kohut und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Topiramate, Fatty Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction–associated steatotic liver disease (MASLD) is a common disease in children. Lifestyle modification is the primary treatment but difficult to achieve and maintain. Topiramate is a component of an approved weight loss medication (topiramate‐phentermine) in children aged 12 years and older but is more commonly used as a single agent, off‐label, for pediatric obesity. Our aim is to describe change in anthropometrics and laboratory values while providing topiramate treatment of pediatric MASLD.

Methods

Descriptive cohort study including patients aged 95th percentile treated with topiramate for weight loss for ≥3 months from January 1, 2010, to December 30, 2023. The primary outcome was change in serum alanine aminotransferase (ALT) levels from baseline to 3–6 months. Secondary outcomes were changes in BMI z score, glycated hemoglobin, and lipid profile.

Results

Of 43 patients prescribed topiramate, 11 were excluded for nonadherence, leaving 32 (56% boys, 72% non‐Hispanic) for further analyses. With topiramate, ALT levels improved (76 vs 50 U/L, p = 0.001). Further, 43% of patients had either ALT normalization or reduction by >50% from baseline. BMI z score decreased by 0.1 from baseline to 3–6 months. There were no improvements in glycated hemoglobin or lipids. Eight patients (25%) reported mild side effects.

Conclusion

Topiramate, as an adjunct to lifestyle intervention, may be considered in the treatment of pediatric MASLD, specifically in the context of failed lifestyle modification and inability to tolerate or qualify for other obesity pharmacotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TopiramateFatty LiverHumansMaleChildFemaleCohort StudiesBody Mass IndexAlanine TransaminaseAdolescentTreatment OutcomeWeight LossPediatric ObesityGlycated Hemoglobin

Stichwörter der Autor:innen

childrenmetabolic dysfunction‐associated steatotic liver diseasenonalcoholic fatty liver diseaseobesity pharmacotherapy

Substanzen

TopiramateAlanine TransaminaseGlycated Hemoglobin

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Gastroenterology and Hepatology, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.

Zitieren

APA

Kohut, T., Tou, A., Carr, E., Xanthakos, S., Arce-Clachar, A. C., Fawaz, R., Valentino, P. L., Panganiban, J., & Mouzaki, M. (2025). Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study. Journal of Parenteral and Enteral Nutrition, 49(3), 308-313. https://doi.org/10.1002/jpen.2722

Vancouver

Kohut T, Tou A, Carr E, Xanthakos S, Arce-Clachar AC, Fawaz R, et al. Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study. Journal of Parenteral and Enteral Nutrition. 2025;49(3):308-313. doi:10.1002/jpen.2722

BibTeX
@article{Kohut2025,
  author = {Kohut, Taisa and Tou, Andrea and Carr, Emily and Xanthakos, Stavra and Arce-Clachar, Ana Catalina and Fawaz, Rima and Valentino, Pamela L and Panganiban, Jennifer and Mouzaki, Marialena},
  title = {Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study},
  journal = {Journal of Parenteral and Enteral Nutrition},
  year = {2025},
  volume = {49},
  number = {3},
  pages = {308--313},
  doi = {10.1002/jpen.2722}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche